Mesenchymal stem cells (MSCs), also referred to as multipotent stromal cells or mesenchymal stromal cells, are present in multiple tissues and capable of differentiating into diverse cell lineages, holding a great promise in developing cell-based therapy for a wide range of conditions. Pelvic floor disorders (PFDs) is a common degenerative disease in women and may diminish a woman’s quality of life at any age. Since the treatments for this disease are limited by the high rates of recurrence and surgical complications, seeking an ideal therapy in the restoration of pelvic floor function is an urgent issue at present. Herein, we summarize the cell sources of MSCs used for PFDs and discuss the potential mechanisms of MSCs in treating PFDs. Specifically, we also provide a comprehensive review of current preclinical and clinical trials dedicated to investigating MSC-based therapy for PFDs. The novel therapy has presented promising therapeutic effects which include relieving the symptoms of urinary or fecal incontinence, improving the biological properties of implanted meshes and promoting the injured tissue repair. Nevertheless, MSC-based therapies for PFDs are still experimental and the unstated issues on their safety and efficacy should be carefully addressed before their clinical applications.

中文翻译：

---

女性骨盆底疾病的基于MSC的治疗。

间充质干细胞（MSC），也称为多能基质细胞或间充质基质细胞，存在于多个组织中，能够分化为多种细胞谱系，在开发基于细胞的多种疾病的疗法中具有广阔的前景。骨盆底疾病（PFDs）是女性常见的变性疾病，可能会降低女性在任何年龄段的生活质量。由于该疾病的治疗受到复发率高和手术并发症的限制，因此在恢复骨盆底功能方面寻求理想的治疗方法是当前的紧迫问题。在这里，我们总结了用于PFD的MSCs的细胞来源，并讨论了MSCs治疗PFDs的潜在机制。特别，我们还提供了有关专门用于研究基于MSC的PFD治疗的临床前和临床试验的全面综述。新型疗法已显示出令人鼓舞的治疗效果，包括减轻尿失禁或大便失禁的症状，改善植入网片的生物学特性以及促进受损组织的修复。尽管如此，基于MSC的PFD疗法仍处于实验阶段，在其临床应用之前应仔细解决其安全性和有效性尚未阐明的问题。